Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Krieg

Showing results (11-20 of 722) with videos related to

Pageof 73
Sort By:
Molecular Therapy. Nucleic Acids|January 25, 2013
Targeting LDL Cholesterol With LNAArthur M Krieg
Nature Immunology|April 27, 2002
A role for Toll in autoimmunityArthur M Krieg
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 21, 2007
The CpG motif: implications for clinical immunologyA M Krieg
Proceedings of the American Thoracic Society|July 4, 2007
Antiinfective applications of toll-like receptor 9 agonistsArthur M Krieg
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 29, 2017
Rigging Innate Immunity against the FluArthur M Krieg
Nature Medicine|July 2, 2003
CpG motifs: the active ingredient in bacterial extracts?Arthur M Krieg
Current Opinion in Immunology|February 19, 2000
The role of CpG motifs in innate immunityA M Krieg
Antisense & Nucleic Acid Drug Development|July 12, 2001
From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNAA M Krieg
Nucleic Acid Therapeutics|February 23, 2012
CpG still rocks! Update on an accidental drugArthur M Krieg
Oncogene|January 8, 2008
Toll-like receptor 9 (TLR9) agonists in the treatment of cancerA M Krieg
Pageof 73

Showing results (11-20 of 722) with videos related to

Sort By:
Pageof 73
Molecular Therapy. Nucleic Acids|January 25, 2013
Targeting LDL Cholesterol With LNAArthur M Krieg
Nature Immunology|April 27, 2002
A role for Toll in autoimmunityArthur M Krieg
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 21, 2007
The CpG motif: implications for clinical immunologyA M Krieg
Proceedings of the American Thoracic Society|July 4, 2007
Antiinfective applications of toll-like receptor 9 agonistsArthur M Krieg
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 29, 2017
Rigging Innate Immunity against the FluArthur M Krieg
Nature Medicine|July 2, 2003
CpG motifs: the active ingredient in bacterial extracts?Arthur M Krieg
Current Opinion in Immunology|February 19, 2000
The role of CpG motifs in innate immunityA M Krieg
Antisense & Nucleic Acid Drug Development|July 12, 2001
From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNAA M Krieg
Nucleic Acid Therapeutics|February 23, 2012
CpG still rocks! Update on an accidental drugArthur M Krieg
Oncogene|January 8, 2008
Toll-like receptor 9 (TLR9) agonists in the treatment of cancerA M Krieg
Pageof 73